Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as a factor concentrate for intravenous use. It treats hemophilia A and related bleeding disorders in patients requiring factor VIII replacement. GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octanate is used in the management of hereditary and acquired disorders affecting the coagulation cascade, particularly hemophilia A. - Hemophilia A: Provides essential factor VIII to control and prevent bleeding episodes. - Acquired factor VIII deficiency: Replaces deficient factor VIII to restore normal clotting function. - Surgical prophylaxis in hemophilia A patients: Maintains adequate factor VIII levels during operative procedures to reduce peri‑operative bleeding.

Side effects associated with Octanate are generally related to its protein nature and the infusion process.

Common Side Effects: - Mild fever - Headache - Nausea - Injection site redness - Transient hypertension - Mild rash

Serious or Rare Side Effects: - Anaphylactic reaction - Development  ...  ...  ...  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .

Octanute     ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... .

-      ...  …  ....  ... ...  ... ...  ... . -   …  ....  … n  … … """"  … "  … "  "  " " " " " " " " " " " " " " ". -  … … … ...

      ...